PMC7516693_01
Sectorial scanning of uncinate process and tail of pancreas. (a) Hypoechoic lesion, homogeneous and well-delimited in the uncinate process and (b) another lesion with the same characteristics but larger in the pancreas tail.
CRIGM2020-7136897.001.jpg
PMC7516693_01_CRIGM2020-7136897.001.jpg
fig1
She underwent endoscopic ultrasound (EUS) which confirmed the finding of abdominal US but detected two more hypoechoic, homogeneous, round areas, with well-defined limits, of soft consistency to elastography, two located in the uncinate process and one in the pancreatic tail, measuring 7 x 8 mm, 11 x 10 mm, and 19 x 12 mm, respectively (Figures 1 and 2).
Elastography performed with a sectorial endoscopic ultrasound device. (a) Elastography of uncinate hardened process lesion (blue image). (b) Yellow arrow indicating hypoechoic lesion of uncinate process.
CRIGM2020-7136897.002.jpg
PMC7516693_01_CRIGM2020-7136897.002.jpg
fig2
She underwent endoscopic ultrasound (EUS) which confirmed the finding of abdominal US but detected two more hypoechoic, homogeneous, round areas, with well-defined limits, of soft consistency to elastography, two located in the uncinate process and one in the pancreatic tail, measuring 7 x 8 mm, 11 x 10 mm, and 19 x 12 mm, respectively (Figures 1 and 2).
(a) and (b) EUS-FNA with Procore 20G needle.
CRIGM2020-7136897.003.jpg
PMC7516693_01_CRIGM2020-7136897.003.jpg
fig3
EUS-FNA core biopsy was performed on all lesions with a ProCore 20G needle (Cook Medical) (Figure 3).
Material obtained through EUS-FNA and sent for histological and immunohistochemical study. (a) Hematoxylin-eosin revealing atypical microducts and (b) GATA3-labeled immunohistochemistry (+) -secondary breast carcinoma.
CRIGM2020-7136897.004.jpg
PMC7516693_01_CRIGM2020-7136897.004.jpg
fig4
The immunohistochemistry of the material was positive for the GATA3 marker, which concluded that it was an invasive carcinoma of mammary origin in the form of triple negative discesa cells (estrogen negative, progesterone negative, and HER2 negative receptors) (Figure 4).